Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...
News-Medical.Net on MSN
Artificial intelligence unlocks new frontiers in RNA drug design
In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...
Explore the role of patient-derived biology in enhancing antibody-drug conjugates for more effective cancer treatment.
Vietnam Investment Review on MSN
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ...
The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, science-forward drug development. By reducing reliance on animal models and ...
This article is based on a poster originally authored by Peter Hsueh, Lili Qin, Jane Liu and Wenlin Ren. Target proteins are central to the antibody discovery process. These reagents play a critical ...
Valink Therapeutics ("Valink"), a private biotechnology company developing next-generation therapeutics with a focus on bispecific antibody-drug conjugates (bsADCs) and complementary modalities, and ...
Vin Singh Founder and Chief Executive Officer BullFrog AI Holdings, Inc.
Harbour BioMed inks long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates: Shanghai, China Tuesday, December 30, 2025, 13:00 Hr ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback